Is survodutide FDA-approved, and what does the research show?

What is survodutide?

Survodutide is an investigational peptide drug ³. Boehringer Ingelheim develops it under license from Zealand Pharma ², ¹⁰. It is a dual agonist: one molecule that switches on two hormone receptors, the glucagon receptor and the GLP-1 receptor ¹, ².

GLP-1, glucagon-like peptide-1, is an incretin hormone, which prompts the pancreas to release insulin after a meal ¹¹. Semaglutide acts on the GLP-1 receptor, and tirzepatide acts on the GLP-1 and GIP receptors; survodutide pairs GLP-1 with glucagon instead ¹¹, ². Its trials have used the code name BI 456906 ¹².

Is survodutide FDA-approved?

Survodutide is not FDA-approved: Drugs@FDA lists no approved survodutide product as of November 9, 2026 ⁴. It is an investigational drug studied in phase 3 trials, two still recruiting ², ⁵, ⁶, ⁷, ⁸. The manufacturer's own release of April 28, 2026 says it "has not been approved for use" and that its "efficacy and safety has not been established" ¹⁰. No approved product means no FDA label: the prescribing and safety information an approved drug carries does not exist for survodutide ⁴.

Boehringer Ingelheim says FDA granted survodutide Fast Track designation in May 2021 and Breakthrough Therapy designation in September 2024, both for MASH with moderate or advanced fibrosis ¹⁰. A designation is not an approval. FDA describes Breakthrough Therapy designation as "a process designed to expedite the development and review of drugs" for a serious condition ¹³. It applies where early evidence suggests a substantial improvement over available therapy ¹³. The company's release gives no filing date; it says further trial results are expected during 2026 ¹⁰.

See the FDA status of every peptide, updated weekly.

How does survodutide work?

Survodutide acts on two receptors, the glucagon receptor and the GLP-1 receptor ¹, ². Drugs that act on the GLP-1 receptor stimulate insulin release after food, delay stomach emptying, and curb glucagon release when blood sugar is high ¹¹. The glucagon arm's contribution is proposed. The SYNCHRONIZE-MASLD authors write that glucagon receptor activity in the liver includes "increased fatty acid oxidation, which may enhance liver fat clearance" ². They add that the mechanisms "remain to be fully elucidated" ².

The two receptors have opposing effects on blood sugar, so the balance between them matters ². In laboratory assays survodutide activates the human GLP-1 receptor about eight times more strongly than the glucagon receptor ². The phase 2 MASH trial tested the hypothesis that the pair "may be more effective than GLP-1 receptor agonism alone" for MASH ¹.

What does the research show?

Studied in people: a randomized, double-blind, placebo-controlled phase 2 trial, 387 adults with obesity or overweight and without diabetes, weight change at 46 weeks ¹². Mean weight fell by 6.2% to 14.9% across the four survodutide groups, against 2.8% with placebo ¹². Only 60% of participants completed the 46 weeks, a share similar in the survodutide and placebo groups ¹².

Studied in people: SYNCHRONIZE-1, a randomized, double-blind phase 3 trial, 725 adults with obesity or overweight and without diabetes, weight change at 76 weeks ⁵. Mean weight fell by 12.2% and 13.0% in the two survodutide groups, against 5.4% with placebo ⁵. That is the trial's primary analysis, which counts the effect of participants who stopped early ⁵. Weight loss of at least 5% was reached by 72.6% and 71.9% of the two survodutide groups, against 46.3% on placebo ⁵. Boehringer Ingelheim's release of April 28, 2026 reports up to 16.6% against 3.2% by a different analysis, the "efficacy estimand"; those are the company's figures, not the journal's primary result ¹⁰.

Studied in people: SYNCHRONIZE-2, a randomized, double-blind phase 3 trial, 752 adults with obesity or overweight and type 2 diabetes, weight change at 76 weeks ⁶. Mean weight fell by 8.2% and 9.8% in the two survodutide groups, against 3.9% with placebo ⁶. Glycated hemoglobin, a measure of average blood sugar, fell by 0.9 and 0.8 percentage points from a baseline of 7.4%, against 0.2 points on placebo ⁶. ClinicalTrials.gov records both SYNCHRONIZE trials as completed, each designed to run 76 weeks ¹⁴, ¹⁵.

Studied in people: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial, 216 adults with obesity and at-risk fatty liver disease, liver fat and weight at 48 weeks ². MASLD, metabolic dysfunction-associated steatotic liver disease, is fat in the liver together with a metabolic risk factor ². "At-risk" in this trial meant signs of liver inflammation or scarring on noninvasive tests, or biopsy-confirmed MASH ².

By the treatment-regimen analysis, 68.5% of the survodutide group cut liver fat by at least 30%, against 28.6% on placebo, and weight fell by 8.7% against 1.4% ². The paper's other analysis, the efficacy estimand, gives 84.2% against 24.3% for liver fat and 12.2% against 1.0% for weight ². Participants came from the United States and Spain only, and 41% of the survodutide group and 40% of the placebo group stopped treatment early ², ¹⁶.

Studied in people: a randomized, placebo-controlled phase 2 trial, 293 adults with biopsy-confirmed MASH and fibrosis stage F1 to F3, liver biopsy at 48 weeks ¹. MASH, metabolic dysfunction-associated steatohepatitis, is the progressive form of MASLD, with inflammation and liver cell injury ². Improvement in MASH without worsening of fibrosis occurred in 43% to 62% across the three survodutide groups, against 14% on placebo ¹. Fibrosis improved by at least one stage in 34% to 36% of survodutide participants, against 22% on placebo ¹.

Studied in people: a randomized, double-blind phase 2 trial, 413 adults with type 2 diabetes on metformin, blood sugar at 16 weeks, with an open-label semaglutide arm ⁹. Glycated hemoglobin fell by 0.9 to 1.7 percentage points across the survodutide groups; one lower survodutide group matched semaglutide, 1.46 against 1.47 points ⁹. The higher survodutide groups lost more weight than the semaglutide group, up to 8.7% against 5.3% ⁹. The abstract gives no placebo figure for either measure, and the comparison is one 16-week trial with an unblinded semaglutide arm ⁹.

The published trials ran 76 weeks at most, and none was designed to test heart attacks, strokes or deaths ¹, ², ⁵, ⁶, ¹², ⁹. SYNCHRONIZE-MASLD counted adjudicated major cardiovascular events, 2 against 1 ². SYNCHRONIZE-CVOT, a cardiovascular safety trial of 5,530 adults with obesity or overweight, is recorded as completed in June 2026; its results appear in no source opened for this page ¹⁷. Two phase 3 MASH trials, LIVERAGE and LIVERAGE-Cirrhosis, are recruiting about 1,800 and 1,590 adults, with primary completion dates in 2031 and 2029 ⁷, ⁸.

What are the side effects?

Gastrointestinal effects dominate every survodutide trial. In SYNCHRONIZE-1, adults with obesity or overweight and without diabetes, gastrointestinal adverse events affected 80.9% and 89.7% of the two survodutide groups, against 47.9% on placebo ⁵. No deaths were reported ⁵.

In SYNCHRONIZE-2, adults with obesity or overweight and type 2 diabetes, the figures were 72.8% and 77.7%, against 38.6% ⁶. Both papers describe these events as mostly mild to moderate ⁵, ⁶. In the phase 2 obesity trial, adverse events of any kind affected 91% of survodutide recipients and 75% of placebo recipients ¹².

In the phase 2 MASH trial, 293 adults with MASH and fibrosis, nausea affected 66% of survodutide participants against 23% on placebo ¹. Diarrhea affected 49% against 23%, and vomiting 41% against 4% ¹. Serious adverse events occurred in 8% with survodutide and 7% with placebo ¹.

In SYNCHRONIZE-MASLD, 216 adults with obesity and at-risk MASLD, adverse events led 23.3% of the survodutide group to stop treatment, against 10.0% on placebo ². Gastrointestinal events caused most of those stops ². Serious adverse events occurred in 9.6% with survodutide and 11.4% with placebo; one placebo participant died and none on survodutide ². Heart rate rose by a mean 3.6 beats per minute with survodutide at week 52, against 0.8 with placebo ². The trial's adjudicators confirmed no case of drug-induced liver injury, acute pancreatitis, pancreatic cancer or thyroid cancer in the survodutide group; one survodutide participant had gallstones and gallbladder inflammation ².

FDA has approved no survodutide product, so no FDA label exists to quote on safety ⁴.

In sport

Survodutide is not named on WADA's 2026 Prohibited List ¹⁸. WADA is the World Anti-Doping Agency. Neither its peptide-hormone section S2 nor its metabolic-modulator section S4 names survodutide, and the list mentions neither glucagon nor GLP-1 ¹⁸. Section S0 of the list prohibits at all times "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use)" ¹⁸. FDA's record is the only regulator's record read here, and it shows no approval ⁴; this page draws no conclusion on whether S0 covers survodutide.

What JumpstartMD offers

JumpstartMD does not prescribe survodutide. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 9, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.